SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.61+5.2%Nov 6 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (7530)12/17/2002 9:20:42 PM
From: Biomaven  Read Replies (2) of 52153
 
V1,

Congratulations to you as well - vindication at long last for your views on Bexxar.

Do you have any sense from the briefing materials or from the AC meeting today of what lay behind the overall Bexxar debacle all these years? Was it the original CLTR decision not to do comparative trials but instead to compare the length of remission to the prior remission length? How much was it the FDA just being difficult and how much was it badly designed/conducted trials?

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News